Minimal Residual Disease Therapeutic Pipeline 2025

DelveInsight's comprehensive 2025 analysis of the Minimal Residual Disease pipeline delivers extensive intelligence on over 8 companies and more than 8 investigational therapies currently advancing through development. This detailed examination encompasses drug candidate profiles across all developmental phases, from preclinical research through clinical trials. The assessment evaluates therapeutic candidates by product classification, developmental phase, administration method, and molecule type, while also documenting discontinued programs in this therapeutic area.

Curious about the latest updates in the Minimal Residual Disease Pipeline? Click here to explore the therapies and trials making headlines @ Minimal Residual Disease Pipeline Outlook Report

Key Highlights from the Pipeline Analysis

• On 02 October 2025, Pfizer revealed an investigation to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants diagnosed with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants will either receive elranatamab (arm A and C) as a subcutaneous injection at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will span approximately five years.

• The current landscape shows a dynamic field with over 8 companies actively advancing more than 8 therapeutic candidates for Minimal Residual Disease management.

• Key pharmaceutical developers include Poxel, Genentech, AmMax Bio, Elicio Therapeutics, Precigen Inc., and others.

• Notable investigational therapies include Lenalidomide, Elranatamab, Chemotherapy, Midostaurin, Mitoxantrone, Liposomal daunorubicin, Gemtuzumab ozogamicin, and additional candidates.

Want to know which companies are leading innovation in Minimal Residual Disease? Dive into the full pipeline insights @ Minimal Residual Disease Clinical Trials Assessment

Understanding Minimal Residual Disease

Minimal residual disease (MRD) refers to the small quantity of cancer cells that persist in the body following treatment, even when no visible signs or symptoms of malignancy are present. These residual cells possess the potential to become active, proliferate, and ultimately lead to disease recurrence. MRD can persist because certain cancer cells may not have responded completely to therapy, or they may have developed treatment resistance. Detecting and monitoring MRD is critical, as it helps evaluate treatment effectiveness and guide subsequent therapeutic decisions to prevent relapse. MRD typically does not cause noticeable symptoms because the number of remaining cancer cells is extremely small. Unlike active malignancy, MRD does not produce physical manifestations such as pain, fatigue, or weight loss. However, if MRD progresses to disease relapse, symptoms may emerge depending on the cancer type, including weakness, abnormal blood counts, or organ dysfunction.

Featured Investigational Therapies

AMB-066: AmMax Bio AMB-066 represents a potent monoclonal antibody targeting the colony stimulating factor 1 receptor (CSF1R) that will be clinically evaluated for treating patients with CRC MRD. The antibody has been tested in approximately 200 patients and healthy subjects across five clinical trials for other indications via intravenous, intra-articular and subcutaneous injections. It has demonstrated generally favorable safety and tolerability across all studies. This compound is currently in Phase II clinical trial stages for treating Minimal residual disease.

ELI-002: Elicio Therapeutics Elicio's lead product candidate, ELI-002, represents a structurally novel investigational AMP cancer vaccine that targets malignancies driven by mutations in the KRAS-gene—a prevalent driver of many human cancers. ELI-002 is comprised of two powerful components built with Elicio's AMP technology consisting of AMP-modified mutant KRAS peptide antigens and ELI-004, an AMP-modified CpG oligodeoxynucleotide adjuvant that is available as an off-the-shelf subcutaneous administration. This compound is currently in Phase I clinical trial stages for treating Minimal residual disease.

If you're tracking ongoing Minimal Residual Disease Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Minimal Residual Disease Treatment Drugs

Report Coverage and Analysis

This comprehensive pipeline report delivers intelligence on:

• Detailed profiles of pharmaceutical companies developing Minimal Residual Disease therapeutics, including aggregate therapy portfolios from each organization.

• Assessment of therapeutic candidates classified by early-stage, mid-stage, and late-stage development phases.

• Active and inactive (dormant or discontinued) pipeline programs across participating companies.

• Categorization of investigational drugs by developmental stage, delivery route, target receptor, treatment approach (monotherapy or combination), mechanism of action, and molecular classification.

• In-depth examination of partnerships (industry collaborations and academic alliances), licensing arrangements, and funding details relevant to future market advancement.

Featured Companies

Poxel, Genentech, AmMax Bio, Elicio Therapeutics, Precigen Inc. and others.

Route of Administration Categories

Pipeline products are organized by delivery method:

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Molecular Type Classifications

Investigational products are categorized by molecular structure:

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

From emerging drug candidates to competitive intelligence, the Minimal Residual Disease Pipeline Report covers it all - check it out now @ Minimal Residual Disease Market Drivers and Barriers, and Future Perspectives

Report Scope

• Geographic Coverage: Global

• Featured Companies: Poxel, Genentech, AmMax Bio, Elicio Therapeutics, Precigen Inc. and others

• Pipeline Therapies: Lenalidomide, Elranatamab, Chemotherapy, Midostaurin, Mitoxantrone, Liposomal daunorubicin, Gemtuzumab ozogamicin, and others

• Product Type Assessment: Monotherapy, Combination therapy, Mono/Combination approaches

• Clinical Stage Assessment: Discovery, Preclinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Minimal Residual Disease Treatment landscape in this detailed analysis @ Minimal Residual Disease Emerging Drugs and Major Players

Report Structure

1. Introduction

2. Executive Summary

3. Minimal residual disease: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Minimal residual disease- DelveInsight's Analytical Perspective

7. Late Stage Products (Phase III)

8. Drug Name: Company Name

9. Drug profiles in the detailed report.....

10. Mid Stage Products (Phase II)

11. AMB-066: AmMax Bio

12. Drug profiles in the detailed report.....

13. Early Stage Products (Phase I)

14. ELI-002: Elicio Therapeutics

15. Drug profiles in the detailed report.....

16. Preclinical and Discovery Stage Products

17. Drug Name: Company Name

18. Drug profiles in the detailed report.....

19. Inactive Products

20. Minimal residual disease Key Companies

21. Minimal residual disease Key Products

22. Minimal residual disease- Unmet Needs

23. Minimal residual disease- Market Drivers and Barriers

24. Minimal residual disease- Future Perspectives and Conclusion

25. Minimal residual disease Analyst Views

26. Minimal residual disease Key Companies

27. Appendix

About DelveInsight

DelveInsight operates as a premier healthcare-focused market research and consulting organization, delivering high-caliber market intelligence and analytical insights that empower informed business decision-making. Supported by seasoned industry specialists and comprehensive expertise in life sciences and healthcare domains, the firm provides tailored research solutions and strategic insights to a global client base. Engage with our team to access premium-quality, precise, and current intelligence that positions you ahead of market developments.

Contact Us 

Kanishk

kkumar@delveinsight.com